September 20, 2017 / 5:08 AM / 3 months ago

BRIEF-Argenx reaches 50% enrollment in phase 2 clinical trial of ARGX-113

Sept 20 (Reuters) - ARGENX NV:

* REG-ARGENX REACHES 50% ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF ARGX-113 IN IMMUNE THROMBOCYTOPENIA

* ARGX-113 IS ALSO BEING STUDIED IN A PHASE 2 PROOF-OF-CONCEPT STUDY FOR TREATMENT OF MYASTHENIA GRAVIS (MG) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below